<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149646">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872988</url>
  </required_header>
  <id_info>
    <org_study_id>CF12045</org_study_id>
    <secondary_id>JIRB11-036-A</secondary_id>
    <nct_id>NCT01872988</nct_id>
  </id_info>
  <brief_title>Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma</brief_title>
  <official_title>Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Institute of Pathology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and
      chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia.
      Transarterial chemoembolization (TACE) is the standard treatment for patients with
      unresectable HCC in the BCLC intermediate stage, but the HCC recurrence rates and long-term
      mortality rates are quite high. These intermediate-staged HCC patients usually need repeated
      TACE due to tumor recurrence, and they may die of HCC progression or liver decompensation
      after repeated TACE. Improved liver function and decreased liver disease progression due to
      oral antiviral therapy have been proven to be effective for chronic hepatitis B, and oral
      antiviral therapy may keep better liver reserve and provide better chance for HCC patients
      received TACE. In addition, chronic HBV infection is one of the most important factors for
      HCC development, and antiviral therapy can improve the outcomes after curative treatment.
      However, the evidence of improving outcomes of HCC patients underwent TACE by oral antiviral
      therapy is lacking. Moreover, Tenofovir Disoproxil Fumarate (TDF) is one of the most potent
      oral antiviral agents, and its safety and very low long-term viral resistance rate have been
      also reported.  There is no study to evaluate the impacts of TDF for HBV-related HCC
      patients underwent TACE. Until now, routine antiviral therapy for HBV-related HCC patients
      underwent TACE has still not been recommended by current guidelines. The hypothesis of this
      study is that a potent oral antiviral therapy for patients with HBV-related HCC patients
      receiving TACE improve patients' outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is randomized double-blind placebo-controlled trial that will be conducted in referral
      teaching hospitals in Taiwan. This trial will recruit 320 patients fulfilling all of the
      following criteria: patients more than 20 years old, HCCs diagnosed by AASLD image criteria
      or pathology, medium-sized HCCs in BCLC intermediate stage and not more than 5 cm in maximum
      diameter and not more than 5 tumors that TACE is indicated, chronic HBV carrier (HBsAg+)
      with detectable HBV DNA in blood, ECOG performance status (PST) 0-2, Child-Pugh score ≦7,
      serum bilirubin &lt; 2 mg/dL and prothrombin time (PT) prolongation &lt; 3 seconds, and
      willingness to adhere to treatment and follow-up plans. Patients are ineligible if they have
      any of the following exclusion criteria: any vascular invasion by tumors, extra-hepatic
      metastasis, concurrent any other malignancy, concomitant immunosuppressive therapy, previous
      any HCC treatment, previous or current any antiviral therapy for HBV, concomitant other
      therapies for HCC except TACE, liver cirrhosis with severe gastroesophageal varices (EVF3 or
      with red color sign), poorly-controlled ascites or hepatic encephalopathy, contraindication
      for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage,
      contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc., chronic renal
      failure with eGFR &lt; 60, concurrent any other chronic viral hepatitis with HCV, HDV, or HIV).
      The Primary endpoints of this study will be 1-, 3-year overall survival, and the secondary
      endpoints of this study will be time to tumor progression and time to liver decompensation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 3-year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to tumor progression</measure>
    <time_frame>1- and 3-year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to liver decompensation</measure>
    <time_frame>1- and 3-year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tenofovir treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start to administer Tenofovir treatment 300mg PO QD  within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Administer Tenofovir to HCC patients who are indicated for TACE after randomization</description>
    <arm_group_label>Tenofovir treatment</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administer Placebo to HCC patients who are indicated for TACE after randomization</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. more than 20 years old

          2. HCCs diagnosed by AASLD image criteria or pathology

          3. Intermediate-stage HCCs that TACE is indicated

          4. chronic HBV carrier with detectable HBV DNA in blood

          5. ECOG performance status (PST) 0-2

          6. Child-Pugh score ≦7

          7. serum bilirubin &lt; 2 mg/dL

          8. prothrombin time prolongation &lt; 3 seconds

          9. willingness to adhere to treatment and follow-up plans -

        Exclusion Criteria:

          1. any vascular invasion by tumors

          2. extra-hepatic metastasis

          3. concurrent any other malignancy

          4. concomitant immunosuppressive therapy

          5. HCC recurrence within 2 years of previous curative treatment

          6. antiviral therapy for chronic hepatitis B within 6 months before HCC diagnosis

          7. concomitant other therapies for HCC except TACE

          8. liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign),
             poorly-controlled ascites or hepatic encephalopathy

          9. contraindication for invasive procedures such as recent gastrointestinal bleeding or
             cerebral hemorrhage

         10. contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc.

         11. chronic renal failure with eGFR &lt; 60

         12. concurrent any other chronic viral hepatitis with HCV, HDV, or HIV) -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Ying Wu, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaw-Town Lin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fu Jen Catholic University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun-Ying Wu, MD, PhD, MPH</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>3304</phone_ext>
    <email>chun@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teng-Yu Lee, MD</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>3316</phone_ext>
    <email>tengyulee@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chia-Yi Christine Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <zip>539</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chi-Yi Chen, MD</last_name>
      <phone>886-5-2765041</phone>
      <email>01290@cych.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chi-Yi Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao-Chun Hsu, MD</last_name>
      <phone>886-7-6150011</phone>
      <phone_ext>2980</phone_ext>
      <email>gatsbyhsu@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Yao-Chun Hsu, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Ying Wu, MD</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>3304</phone_ext>
      <email>chun@vghtc.gov.tw</email>
    </contact>
    <contact_backup>
      <last_name>Teng-Yu Lee, MD</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>3316</phone_ext>
      <email>tengyulee@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chun-Ying Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teng-Yu Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jen-I Hwang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hosp</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wen-Hsiung Chang, MD</last_name>
      <phone>02-2543-3535</phone>
      <email>d220533864@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Wen-Hsiung Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www3.vghtc.gov.tw/der/IRB/INDEX.HTM</url>
    <description>The Institutional Review Board of Taichung Veterans General Hospital</description>
  </link>
  <reference>
    <citation>Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.</citation>
    <PMID>12049862</PMID>
  </reference>
  <reference>
    <citation>Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71.</citation>
    <PMID>11981766</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 7, 2013</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Veterans General Hospital</investigator_affiliation>
    <investigator_full_name>Chun-Ying Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>antiviral therapy</keyword>
  <keyword>intermediate stage</keyword>
  <keyword>hepatitis B virus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
